Even in the shade
Clinical practices and adoption rates among providers Patient compliance and adherence Mixed sentiments abound in both the healthcare and insurance industries about actual take-up rates, with some bullish about the outlook given the hype generated both in the clinical setting and commercially
Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk
This ratio represents the percentage of income required to maintain a full year of GLP-1 treatment, revealing where affordability challenges are most severe
A recent study from the University of Copenhagen highlights new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, focusing on potential bone density loss
Additionally, the FDA generally prohibits the individual importation of prescription biologics like GLP-1s due to safety and temperature control concerns